ODAM IMMUNITET TANQISLIGI VIRUSI INFEKSIYASI BILAN BIRGALIKDA KECHUVCHI VIRUS ETIOLOGIYALI SURUNKALI GEPATITLARNING KLINIK-LABORATOR XUSUSIYATLARI

Authors

  • Nabiyeva Nasiba Axmatovna Respublika ixtisoslashtirilgan Epidemiologiya, mikrobiologiya, yuqumli va parazitar kasalliklar ilmiy-amaliy tibbiyot markazi Navoiy viloyati filialining havo-tomchi infeksiyalari bo‘limi yuqumli kasalliklar shifokori.

Keywords:

odam immunitet tanqisligi virusi infeksiyasi; surunkali gepatit B; surunkali gepatit C; birgalikda kechuvchi infeksiya; jigar fibrozi; jigar sirrozi; virus yuklamasi; jigar fermentlari; immun tanqisligi; laborator tashxis.

Abstract

Mazkur ilmiy maqolada odam immunitet tanqisligi virusi infeksiyasi fonida kechadigan virus etiologiyali surunkali gepatit B va surunkali gepatit C ning klinik-laborator xususiyatlari tahlil qilindi. Ushbu birgalikda kechuvchi infeksiyalar umumiy yuqish yo‘llari, immun tizimning chuqur buzilishi, jigar shikastlanishining tezlashishi hamda davolash jarayonida kuzatiladigan murakkab dori o‘zaro ta’sirlari bilan tavsiflanadi. Maqolaning maqsadi klinik belgilar, biokimyoviy o‘zgarishlar, virusologik ko‘rsatkichlar, gematologik siljishlar va jigar fibrozini baholash masalalarini tizimli yoritishdan iborat. Adabiyotlar tahlili shuni ko‘rsatadiki, odam immunitet tanqisligi virusi surunkali gepatit B da virusning ko‘payishini kuchaytiradi, antigenlarning uzoq saqlanishiga, serologik javobning zaiflashishiga va fibroz hamda jigar sirrozi tez rivojlanishiga yordam beradi. Surunkali gepatit C bilan birga kechishda esa yallig‘lanish-faollik ko‘rsatkichlari hamisha yuqori bo‘lmasa-da, fibrozning sur’ati, portal gipertenziya, jigar dekompensatsiyasi va jigar hujayrali saratoni xavfi ortadi. Klinik manzara ko‘pincha nospetsifik asteniya, holsizlik, ishtaha pasayishi, ko‘ngil aynishi, o‘ng qovurg‘a ostida noqulaylik va vazn kamayishi bilan boshlanadi; immun tanqisligi kuchli bo‘lganda belgilar kam namoyon bo‘lishi mumkin. Laborator tashxis jigar fermentlari, bilirubin, oqsil fraksiyalari, qonning shaklli elementlari, ivish tizimi, virus yuklamasi, serologik markerlar va jigar qattiqligini o‘lchash natijalarini birgalikda baholashni talab qiladi. Natijalar integrallashgan skrining, erta tashxis, muntazam monitoring va bemor uchun moslashtirilgan antiviral yondashuv jigar bilan bog‘liq asoratlar yukini kamaytirishini ko‘rsatadi.

References

Jahon sog‘liqni saqlash tashkiloti. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection. Jeneva: Jahon sog‘liqni saqlash tashkiloti; 2024. 272 bet.

Jahon sog‘liqni saqlash tashkiloti. Updated recommendations on simplified service delivery and diagnostics for hepatitis C infection. Jeneva: Jahon sog‘liqni saqlash tashkiloti; 2022. 32 bet.

Jahon sog‘liqni saqlash tashkiloti. Hepatitis B: fact sheet. Jeneva: Jahon sog‘liqni saqlash tashkiloti; 2025.

Platt L, French C, McGowan C, Sabin K, Gower E, Trickey A va boshqalar. Prevalence and burden of hepatitis B virus coinfection among people living with human immunodeficiency virus: a global systematic review and meta-analysis. Journal of Viral Hepatitis. 2020; 27(3):294-315.

Rashti R, Alavian S, Moradi Y, Sharafi H, Mohamadi Bolbanabad A, Roshani D va boshqalar. Global prevalence of hepatitis C virus and or hepatitis B virus coinfections among people who inject drugs and female sex workers who live with human immunodeficiency virus: a systematic review and meta-analysis. Archives of Virology. 2020; 165(9):1947-1958.

Zheng Y, Ma S, Xiong Y, Fan X. Efficacy and safety of direct acting antiviral regimens for hepatitis C virus and human immunodeficiency virus coinfection: systematic review and network meta-analysis. Journal of Gastroenterology and Hepatology. 2020; 35(9):1477-1487.

World Health Organization. Global health sector strategies on human immunodeficiency virus, viral hepatitis and sexually transmitted infections for 2022-2030. Jeneva: World Health Organization; 2022.

Terrault N, Lok A, McMahon B, Chang K, Hwang J, Jonas M va boshqalar. Update on prevention, diagnosis, and treatment of chronic hepatitis B. Hepatology. 2018; 67(4):1560-1599.

European Association for the Study of the Liver. Recommendations on treatment of hepatitis C. Journal of Hepatology. 2020; 73(5):1170-1218.

European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. Journal of Hepatology. 2017; 67(2):370-398.

Ikeda K, Kawaguchi Y, Kobayashi M, Saitoh S, Suzuki F, Tsubota A va boshqalar. Direct acting antiviral treatment and liver outcomes in hepatitis C virus infection. Clinical Liver Disease. 2021; 17(2):74-81.

World Health Organization. Global hepatitis report 2024. Jeneva: World Health Organization; 2024.

Downloads

Published

2026-07-29

How to Cite

Nabiyeva Nasiba Axmatovna. (2026). ODAM IMMUNITET TANQISLIGI VIRUSI INFEKSIYASI BILAN BIRGALIKDA KECHUVCHI VIRUS ETIOLOGIYALI SURUNKALI GEPATITLARNING KLINIK-LABORATOR XUSUSIYATLARI. IQRO , 22(02), 525–533. Retrieved from https://www.wordlyknowledge.uz/index.php/iqro/article/view/8753